vs
OFG BANCORP（OFG）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
OFG BANCORP的季度营收约是再鼎医药的1.5倍（$184.3M vs $127.1M），再鼎医药同比增速更快（17.1% vs 0.9%），OFG BANCORP自由现金流更多（$199.3M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 2.8%）
OFG Bancorp成立于1964年，总部位于波多黎各圣胡安，是东方银行的金融控股公司。公司通过东方银行、东方金融服务有限责任公司、东方保险有限责任公司等核心子公司，主要面向波多黎各和美属维尔京群岛市场，提供多元化的零售与商业银行、贷款、财富管理相关产品、服务及技术解决方案。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
OFG vs ZLAB — 直观对比
营收规模更大
OFG
是对方的1.5倍
$127.1M
营收增速更快
ZLAB
高出16.2%
0.9%
自由现金流更多
OFG
多$226.0M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
2.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $184.3M | $127.1M |
| 净利润 | $55.9M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 25.7% | -54.6% |
| 净利率 | 30.3% | — |
| 营收同比 | 0.9% | 17.1% |
| 净利润同比 | 11.0% | — |
| 每股收益（稀释后） | $1.27 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFGZLAB
| Q4 25 | $184.3M | $127.1M | ||
| Q3 25 | $186.2M | $115.4M | ||
| Q2 25 | $182.4M | $109.1M | ||
| Q1 25 | $178.6M | $105.7M | ||
| Q4 24 | $182.7M | $108.5M | ||
| Q3 24 | $174.7M | $101.8M | ||
| Q2 24 | $179.8M | $100.1M | ||
| Q1 24 | $174.4M | $87.1M |
净利润OFGZLAB
| Q4 25 | $55.9M | — | ||
| Q3 25 | $51.8M | $-36.0M | ||
| Q2 25 | $51.8M | $-40.7M | ||
| Q1 25 | $45.6M | $-48.4M | ||
| Q4 24 | $50.3M | — | ||
| Q3 24 | $47.0M | $-41.7M | ||
| Q2 24 | $51.1M | $-80.3M | ||
| Q1 24 | $49.7M | $-53.5M |
毛利率OFGZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率OFGZLAB
| Q4 25 | 25.7% | -54.6% | ||
| Q3 25 | 33.0% | -42.3% | ||
| Q2 25 | 36.1% | -50.3% | ||
| Q1 25 | 33.3% | -53.3% | ||
| Q4 24 | 28.9% | -62.6% | ||
| Q3 24 | 35.4% | -66.6% | ||
| Q2 24 | 39.6% | -76.0% | ||
| Q1 24 | 38.9% | -80.7% |
净利率OFGZLAB
| Q4 25 | 30.3% | — | ||
| Q3 25 | 27.8% | -31.2% | ||
| Q2 25 | 28.4% | -37.3% | ||
| Q1 25 | 25.5% | -45.8% | ||
| Q4 24 | 27.6% | — | ||
| Q3 24 | 26.9% | -40.9% | ||
| Q2 24 | 28.4% | -80.2% | ||
| Q1 24 | 28.5% | -61.4% |
每股收益（稀释后）OFGZLAB
| Q4 25 | $1.27 | $-0.05 | ||
| Q3 25 | $1.16 | $-0.03 | ||
| Q2 25 | $1.15 | $-0.04 | ||
| Q1 25 | $1.00 | $-0.04 | ||
| Q4 24 | $1.10 | $-0.09 | ||
| Q3 24 | $1.00 | $-0.04 | ||
| Q2 24 | $1.08 | $-0.08 | ||
| Q1 24 | $1.05 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.0B | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.4B | $715.5M |
| 总资产 | $12.5B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OFGZLAB
| Q4 25 | $1.0B | $689.6M | ||
| Q3 25 | $740.3M | $717.2M | ||
| Q2 25 | $851.8M | $732.2M | ||
| Q1 25 | $710.6M | $757.3M | ||
| Q4 24 | $591.1M | $779.7M | ||
| Q3 24 | $680.6M | $616.1M | ||
| Q2 24 | $740.4M | $630.0M | ||
| Q1 24 | $754.4M | $650.8M |
股东权益OFGZLAB
| Q4 25 | $1.4B | $715.5M | ||
| Q3 25 | $1.4B | $759.9M | ||
| Q2 25 | $1.3B | $791.7M | ||
| Q1 25 | $1.3B | $810.8M | ||
| Q4 24 | $1.3B | $840.9M | ||
| Q3 24 | $1.3B | $667.7M | ||
| Q2 24 | $1.2B | $704.2M | ||
| Q1 24 | $1.2B | $762.2M |
总资产OFGZLAB
| Q4 25 | $12.5B | $1.2B | ||
| Q3 25 | $12.2B | $1.2B | ||
| Q2 25 | $12.2B | $1.2B | ||
| Q1 25 | $11.7B | $1.2B | ||
| Q4 24 | $11.5B | $1.2B | ||
| Q3 24 | $11.5B | $985.3M | ||
| Q2 24 | $11.3B | $987.4M | ||
| Q1 24 | $11.2B | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $217.7M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $199.3M | $-26.7M |
| 自由现金流率自由现金流/营收 | 108.1% | -21.0% |
| 资本支出强度资本支出/营收 | 10.0% | 0.5% |
| 现金转化率经营现金流/净利润 | 3.90× | — |
| 过去12个月自由现金流最近4个季度 | $345.4M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流OFGZLAB
| Q4 25 | $217.7M | $-26.0M | ||
| Q3 25 | $39.5M | $-32.0M | ||
| Q2 25 | $35.9M | $-31.0M | ||
| Q1 25 | $83.1M | $-61.7M | ||
| Q4 24 | $252.5M | $-55.8M | ||
| Q3 24 | $58.1M | $-26.8M | ||
| Q2 24 | $95.1M | $-42.2M | ||
| Q1 24 | $61.0M | $-90.1M |
自由现金流OFGZLAB
| Q4 25 | $199.3M | $-26.7M | ||
| Q3 25 | $35.5M | $-35.0M | ||
| Q2 25 | $31.8M | $-33.9M | ||
| Q1 25 | $78.7M | $-63.2M | ||
| Q4 24 | $231.2M | $-58.4M | ||
| Q3 24 | $51.8M | $-28.2M | ||
| Q2 24 | $90.4M | $-42.9M | ||
| Q1 24 | $54.8M | $-91.1M |
自由现金流率OFGZLAB
| Q4 25 | 108.1% | -21.0% | ||
| Q3 25 | 19.1% | -30.4% | ||
| Q2 25 | 17.4% | -31.1% | ||
| Q1 25 | 44.1% | -59.9% | ||
| Q4 24 | 126.5% | -53.8% | ||
| Q3 24 | 29.6% | -27.7% | ||
| Q2 24 | 50.3% | -42.9% | ||
| Q1 24 | 31.4% | -104.5% |
资本支出强度OFGZLAB
| Q4 25 | 10.0% | 0.5% | ||
| Q3 25 | 2.1% | 2.6% | ||
| Q2 25 | 2.3% | 2.6% | ||
| Q1 25 | 2.4% | 1.5% | ||
| Q4 24 | 11.7% | 2.4% | ||
| Q3 24 | 3.6% | 1.3% | ||
| Q2 24 | 2.6% | 0.7% | ||
| Q1 24 | 3.5% | 1.1% |
现金转化率OFGZLAB
| Q4 25 | 3.90× | — | ||
| Q3 25 | 0.76× | — | ||
| Q2 25 | 0.69× | — | ||
| Q1 25 | 1.82× | — | ||
| Q4 24 | 5.02× | — | ||
| Q3 24 | 1.24× | — | ||
| Q2 24 | 1.86× | — | ||
| Q1 24 | 1.23× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFG
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
